|
|
|
|
|
Highlights from the 2023 American Urological Association Annual Meeting |
|
|
|
|
|
|
| AUA Guidelines for the Early Detection of Prostate Cancer |
| John Thomas Wei, MD |
| John Wei presented this year’s update on the AUA Guidelines, focusing on the Early Detection of Prostate Cancer. He concisely summarized the key new guideline recommendations. While multiple studies have demonstrated the benefit of early detection and treatment of clinically significant prostate cancer, screening is a preference sensitive decision that may have many potential downstream implications. |
|
|
|
|
|
|
Imaging/Radiology: Uroradiology I
|
|
| Detection of Clinically Significant Prostate Cancer on MRI: A Comparison of an Artificial Intelligence Model versus Radiologists
|
| Simon Soerensen, MD
|
| Simon Soerensen discussed the comparison of an artificial intelligence model versus radiologists for the detection of clinically significant prostate cancer on MRI. This model is intended to rapidly and accurately identify cancer foci on MRI and compare its performance against radiologists.
|
|
|
|
|
|
|
Prostate Cancer: Advanced (Including Drug Therapy) I
|
|
| Prostate Specific Antigen Analyses in PROpel: Abiraterone and Olaparib Vs Abiraterone and Placebo as First-Line Therapy for mCRPC
|
| Fred Saad, MD, FRSC
|
| In this exploratory analysis, first-line mCRPC treatment with abiraterone and olaparib resulted in higher PSA response rates and prolonged time to PSA progression vs abiraterone and placebo in all patients, with more pronounced improvements in the HRRm and BRCA mutation subgroups.
|
|
|
|
|
|
| Treatment Duration and Long-Term Safety and Tolerability With Darolutamide in nmCRPC: ARAMIS Rollover Study
|
| Neal D. Shore, MD, FACS
|
| Neal Shore discussed data from the ARAMIS rollover study assessing treatment duration and long-term safety and tolerability with darolutamide in nmCRPC. Darolutamide is a structurally distinct and highly potent androgen receptor inhibitor, with low blood-brain barrier penetration and limited potential for clinically relevant drug-drug interactions.
|
|
|
|
|
|
| Treatment Trends in Patients With De Novo Metastatic Prostate Cancer in the Era of Upfront Combination Therapy
|
| Sasaki Daichi, MD
|
| Sasaki Daichi discussed treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy. Given the variability in treatment of patients with metastatic hormone sensitive prostate cancer, Dr. Daichi and colleagues assessed trends in treatment selection for these patients.
|
|
|
|
|
|
|
|
|
|
|
| Prescription Patterns of Systemic Therapy in the Management of Metastatic Castration-Sensitive Prostate Cancer |
| Joseph Black, MD, Ph.D. |
| Since 2015, novel hormonal therapy utilization and treatment intensification has nationally increased for mCSPC and prescription patterns do not vary between rural and urban settings. When compared to urologists, medical oncologists have more readily incorporated newer therapeutics for mCSPC and decreased the usage of LHRH monotherapy for patients with mCSPC. |
|
|
|
|
|
| The Prognostic Role of 68Ga-PSMA PET/CT and the Impact of Metastasis-Directed Therapy on Cancer Progression in Men With Biochemical Recurrence From Prostate Cancer: Results From a Large, Single Institution Series
|
| Daniele Robesti, MD
|
| Use of 68Ga-PSMA PET is recommended for prostate cancer re-staging in patients with either PSA persistence or biochemical recurrence after radical prostatectomy. Since evidence on the role of metastasis directed therapy on progression-free survival is still poor, Daniele Robesti and colleagues aimed at assessing, in patients with positive PSMA PET, whether metastasis-directed therapy may impact on progression-free survival.
|
|
|
|
|
|
| Radioligand Therapy With 177Lu-PSMA-I&T in Patients With Metastatic Castration-Resistant Prostate Cancer: Oncological Outcomes and Toxicity Profile
|
| Baris Esen, MD, Ph.D., FEBU, MSc
|
| PSMA-targeted radioligand therapy with 177Lu-PSMA-617 is associated with prolonged overall survival in patients with mCRPC. However, data regarding the oncological efficacy and toxicity profile of 177Lu-PSMA-I&T is limited. At the 2023 AUA annual meeting, Baris Esen and colleagues aimed to investigate the oncological outcomes and toxicity profile of 177Lu-PSMA-I&T radioligand therapy in patients with mCRPC.
|
|
|
|
|
|
| Exploring the Effect of Metastasis Directed Therapy on Progression Patterns of Patients with Positive 68Ga-PSMA PET/CT and Biochemical Recurrence from Prostate Cancer |
| Antony Pellegrino, MD |
| Antony Pellegrino discussed the effect of MDT on progression patterns of patients with positive 68Ga-PSMA PET/CT and biochemical recurrence from prostate cancer. Indeed, among men with positive PSMA PET for biochemical recurrence after radical prostatectomy, MDT may represent a treatment option. However, there is little evidence regarding the role of MDT in terms of prognostic implications, as well as on the patterns of subsequent clinical recurrence. |
|
|
|
|
|
| Clinical Fracture Incidence in mHSPC and Risk-Reduction Following Addition of Zoledronic Acid to ADT With or Without Docetaxel: Long-Term Results From Two Phase 3 Trials From the STAMPEDE Platform Protocol
|
| Craig Jones, MD
|
| By accessing routinely-collected healthcare data, this study evaluated long-term fracture events amongst patients in STAMPEDE. Fracture rates were clinically notable in M1 and reduced significantly in patients allocated zoledronic acid with ADT ± docetaxel. These data support using bone protective agents to reduce clinically significant fractures in mHSPC.
|
|
|
|
|
|
| The Effect of a Reduced Dose of Apalutamide on Skin-Related Adverse Events in Advanced Prostate Cancer: a Multicenter Retrospective Study |
| Kyo Togashi, MD |
| The incidence of skin-related adverse events of apalutamide was higher in Japanese patients than in the phase 3 SPARTAN and TITAN trials. Additional analyses have suggested that small body size of the Japanese men may result in high levels of apalutamide in the blood. As such, Kyo Togashi and colleagues aimed to evaluate the effect of apalutamide dose reduction on skin-related adverse events and CRPC-free survival in patients with advanced prostate cancer. |
|
|
|
|
|
|
